News
Financial Results for year ended 30 September 2025 and Notice of AGM
09 December 2025, IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, announces its audited results for the year ended 30 September 2025 ("FY25").
Execution of the Group's Innovate Lead Scale strategy across the year has delivered a strong financial performance with 13% revenue growth and a 21% reduction in EBITDA loss. Commercial traction has further accelerated into FY26, resulting in a 27% increase to the order book since the FY25 year-end.
IXICO strengthens Scientific Advisory Board with two prominent global Alzheimer’s Disease and vascular experts
01 December 2025, IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced that it has appointed two leading global experts in the field of Alzheimer’s Disease (AD) and cerebrovascular disease (CVD) as advisors to the Company. Professor Michael Weiner, and Professor Joanna Wardlaw join IXICO’s advisory board with immediate effect.
Global Phase 3 Clinical Trial Contract Win
17 November 2025 IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience precision medicine and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced that it has signed a new commercial contract with a global pharmaceutical company to provide imaging services for a worldwide Phase 3 clinical trial in Huntington’s Disease (HD). The total contract value is over £3.5m over four years.
Capital Markets Day Presentation and Video 2025
Capital Markets Day Presentation and Video 03 November 2025 IXICO plc (AIM: IXI) – London, UK.
Trading update for the year ended 30 September 2025
16 October 2025 IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced a trading update, pre-audit, for its financial year ended 30 September 2025 (“FY25”).
New blood based biomarker contract win and contract extension worth a total of £1.2 million
15 October 2025 IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced that it has signed a new commercial contract to assist in the validation of a diagnostic blood test, reaffirming the Company’s expertise in this area. IXICO has also entered into a contract extension on an existing Alzheimer’s Disease (AD) clinical trial. The combined value of the new contract and contract extension is c. £1.2 million.
IXICO wins "CRO Provider of the Year 2025" at the Precision Medicine Awards!
We’re proud to announce that IXICO has been named CRO Provider of the Year at the Precision Medicine Awards 2025, hosted by Oxford Global. This award celebrates our commitment to advancing precision in neuroscience through cutting-edge neuroimaging and AI-powered analytics.
Global clinical trial contract wins in Alzheimer’s Disease and Friedreich’s Ataxia
12 August 2025 IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced it has signed two separate new commercial contracts to provide neuroimaging services across different core therapeutic indications.
1-8 of 33 results